Education and Training
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Casimersen
- drug: Golodirsen
Eligibility
Inclusion Criteria:
- Completed a clinical trial evaluating casimersen or golodirsen, per protocol.
- Is between 7 and 23 years of age, inclusive, at enrollment.
Other inclusion/exclusion criteria apply.
Ages Eligible for Study
7 Years - 23 Years
Genders Eligible for Study
Male
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting